Dehradun: Punjab Police Bust Drug Manufacturing Racket, 4.5 Lakh Narcotic Pills Seized

Dehradun : The arrest of two peddlers allegedly involved in the smuggling of habit-forming and intoxicating medicines led the district police to an illegal drug manufacturing unit in Dehradun, Uttarakhand.

Its owner Usman Rajpoot was arrested and the police seized 4.05 lakh tablets. The local administration sealed the unit and launched an investigation.

Usman has been brought to Amritsar on police remand. The police said banned drugs were being supplied to different parts of Punjab. The unit was busted following the interrogation of Nishan Sharma of Sunder Nagar and Rajiv Kumar of the Namak Mandi area, who were arrested on December 21. As many as 29,920 tablets of tramadol, a banned drug, and Rs 29,000 were seized from their possession.

Police Commissioner Jaskaran Singh said during interrogation, the duo revealed they had bought the pills from Usman, owner of Rapport Remedies, Dehradun. He said the licence of the unit was cancelled by the Uttarakhand drug authorities in October this year. The officer said despite the cancellation of his firm’s licence, he continued to manufacture tramadol and other intoxicating tablets.

“We have seized the record of the factory and are investigating its links with other suppliers,” he said.

Sources said the unit had been operational for the past several years. Besides Punjab, it supplied drugs to different parts of the country.

Peddlers’ arrest exposed racket

  • Amritsar cops arrested two peddlers on Dec 21, seized 29,920 tablets of banned drug
  • Duo revealed they bought pills from Usman, owner of Rapport Remedies, Dehradun
  • Unit’s licence was cancelled in October, but it continued to make intoxicating drugs
  • Related Posts

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    New Delhi: AstraZeneca’s India-arm has partnered with National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, to build clinical research capabilities at 25 emerging geographies in a bid to extend…

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into papillary-only non-muscle-invasive bladder cancer (NMIBC). Wednesday’s approval comes nearly three months ahead…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

    Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

    ‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

    ‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

    Governments have moved for Price Transparency in Hospitals to help patients cope with bills

    Governments have moved for Price Transparency in Hospitals to help patients cope with bills

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction